Article Sidebar

PDF
Date Published: 17/06/2022
Abstract Views: 363
Views PDF: 169
DOI: https://doi.org/10.51298/vmj.v513i2.2488
Issue
Vol. 513 No. 2 (2022)
Section
Các bài báo
How to Cite
Huy Thịnh, T. ., & Vân Khánh, T. . (2022). IDENTIFYING OF EGFR MUTATION AND EML4-ALK FUSION GENE IN NON SMALL CELL LUNG CANCER. Vietnam Medical Journal, 513(2). https://doi.org/10.51298/vmj.v513i2.2488

IDENTIFYING OF EGFR MUTATION AND EML4-ALK FUSION GENE IN NON SMALL CELL LUNG CANCER

Trần Huy Thịnh1,, Trần Vân Khánh1
1 Hanoi Medical University

Main Article Content

Abstract

Targeted therapy is an effective method for treatment of non small cell lung cancer (NSCLC). However, not all of patients have good response with targeted drugs. Many previous studies demonstrated the close relationship between EGFR and EML4-ALK rearrangement mutation and the response of targeted drugs with tumor. Objectives: Identifying EGFR and EML4-ALK rearrangement mutations in NSCLC patients by realtime PCR and FISH methods. Methods: 95 NSCLC patients were selected for this study; realtime PCR and FISH methods were used to identify EGFR mutation and EML4-ALK rearrangement mutation Results: 48/95 (50,5%) of NSCLC patients have mutation in exon 19 and 21 of EGFR gene; 6/95 (6,3%) of NSCLC patients have EML4-ALK rearrangement mutation.

Article Details

Keywords

Non small cell lung cancer, EGFR, EML4-ALK rearrangement mutation, Targeted therapy

References

1. Jemal A, Siegel 1. R, Ward E (2008). Cancer statistics, CA Cancer J Clin, 58:71-96.
2. Sato M, Shames DS, Gazdar AF, Minna JD (2007). A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2:327-43.
3. Wistuba II, Mao L, Gazdar AF (2002). Smoking molecular damage in bronchial epithelium. Oncogene. 21,7298-306.
4. Wistuba II, Mao L, Gazdar AF (2002), “Smoking molecular damage in bronchial epithelium”, Oncogene, 21, 7298-7306.
5. Lee CK, Brown C, Gralla RJ et al. Impact of EGFR inhibitor in non–small cell lung cancer on progression-free and overall survival: a meta-analysis. Journal of the National Cancer Institute 2013; 105: 595-605.
6. Xu Q, Liu H, Meng S, et al. First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. J Cancer. 2019; 10 (2): 522-529.
7. Martelli MP, Sozzi G, Hernandez L, et al. (2009), "EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues", Am J Pathol, 174 (2), pp. 661-70.
8. Thunnissen E, Bubendorf L, Dietel M, et al. (2012), "EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations", Virchows Arch, 461 (3), pp. 245-57.
9. Scagliotti G, Stahel RA, Rosell R, et al. (2012), "ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development", Eur J Cancer, 48 (7), pp. 961-73.
10. Ngô Quý Châu, Chu Thị Hạnh, Trần Vân Khánh, Lê Hoàn (2014). Dung hợp gen EML4-ALK: Hướng tiếp cận mới trong điều trị nhắm trúng đích với ung thư phổi không tế bào nhỏ. Y học lâm sàng, 77, 11-16.